Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Jan 07, 2024
TickeronGET DAILY SIGNALS
Automated Glory: $BNGO Rises +5.10% with Trader Robot Precision

Automated Glory: $BNGO Rises +5.10% with Trader Robot Precision

In the ever-evolving landscape of active trading, AI-driven robots have become key players, providing insights and executing trades with precision. In this article, we delve into the recent performance of AI trading bots, particularly those accessible at "Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)," which demonstrated their prowess by generating a notable +strong performance while trading BNGO over the past week.

BNGO's RSI Indicator Signals Transition

One crucial aspect of BNGO's recent trading activity is the Relative Strength Index (RSI) oscillator, which moved out of the overbought zone on December 29, 2023. This shift suggests a potential reversal from an upward trend to a downward one. Tickeron's A.I.dvisor, in analyzing similar instances, found that in 19 out of 20 cases where the RSI moved out of the overbought zone, the stock experienced a subsequent decline. This statistical observation gives traders a 90% likelihood of a downward move, prompting considerations for selling the stock or exploring put options.

Earnings Snapshot and Market Capitalization

Examining the last earnings report on November 09 reveals a notable -100 cents earnings per share, missing the estimated -97 cents. With 1.74 million shares outstanding, BNGO's current market capitalization stands at 59.43 million. It's crucial to note that this performance places BNGO within the Medical Specialties Industry, where the average market capitalization is 6.46 billion. Comparatively, BNGO's market cap appears significantly smaller, highlighting its distinct position within the industry.

Market Cap Comparisons

The Medical Specialties Industry presents a diverse range of market capitalizations, from 27 million to a staggering 3.82 trillion. Noteworthy companies in this sector include MKYSF with the highest valuation at 3.82 trillion and FOGCF at the lower end with a valuation of 27 million. BNGO's market cap, situated at 59.43 million, positions it within the mid-range of this industry spectrum.

Price Movements in the Industry

Understanding the broader market trends in the Medical Specialties Industry is essential. On average, weekly price growth for these stocks remained at 0%, while monthly growth registered at 11%, and quarterly growth at -6%. Within this spectrum, TIPS stood out with an impressive 286% price growth, while NMRD experienced a significant fall at -63%.

Volume Insights

Volume dynamics play a crucial role in understanding market activity. Across the Medical Specialties Industry, the average weekly volume growth was 127%, with monthly growth at 55%, and quarterly growth at 161%. These figures underscore the dynamic nature of trading within this sector and suggest heightened investor interest and participation.

The recent performance of AI trading bots, particularly in handling BNGO amidst changing market conditions, underscores the importance of adapting to evolving trends.

Related Ticker: BNGO

Contributor

Dem Sem's AvatarDem Sem|Expert

Momentum Indicator for BNGO turns negative, indicating new downward trend

BNGO saw its Momentum Indicator move below the 0 level on November 11, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 79 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for BNGO turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 38 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

BNGO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BNGO crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for BNGO entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNGO advanced for three days, in 165 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

BNGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.429) is normal, around the industry mean (4.964). P/E Ratio (-0.382) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (56.876).

The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. BNGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -8%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 4%. STXS experienced the highest price growth at 12%, while RGNT experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 21%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 53
Price Growth Rating: 52
SMR Rating: 81
Profit Risk Rating: 94
Seasonality Score: 18 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of technologies for analysis of large biological molecules

Industry PharmaceuticalsOther

Industry
Biotechnology
Address
9540 Towne Centre Drive
Phone
+1 858 888-7600
Employees
97
Web
https://www.bionano.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.